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Background: Conflicts of interest affect recommendations in clinical guidelines and disclosure of such conflicts is
important. However, not all conflicts of interest are disclosed. Using a public available disclosure list we determined
the prevalence and underreporting of conflicts of interest among authors of clinical guidelines on drug treatments.
Methods: We included up to five guidelines published from July 2010 to March 2012 from each Danish clinical
specialty society. Using the disclosure list of the Danish Health and Medicines Authority, we identified author
conflicts of interest and compared them with the disclosures in the guidelines. For each guideline we extracted
methodological characteristics of guideline development.
Results: Forty-five guidelines from 14 specialty societies were included. Of 254 authors, 135 (53%) had conflicts of
interest, corresponding to 43 of the 45 guidelines (96%) having one or more authors with a conflict of interest.
Only one of the 45 guidelines (2%) disclosed author conflicts of interest. The most common type of conflict of
interest (83 of the 135) was being a consultant, an advisory board member or a company employee. Only 10
guidelines (22%) described the methods used for guideline development, 27 (60%) used references in the text and
11 (24%) graded the types of evidence.
Conclusions: Conflicts of interest were common, but disclosures were very rare. Most guidelines did not describe
how they were developed and many did not describe the evidence behind specific recommendations. Publicly
available disclosure lists may assist guideline issuing bodies in ensuring that all conflicts are disclosed.
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The amount of medical information is overwhelming
and it increases rapidly [1]. Clinical practice guidelines
are therefore an important tool for assisting clinicians
and patients in clinical decision-making [2]. Clinical
practice guidelines should be based on valid scientific
evidence, critical assessment of that evidence, and
objective clinical judgement that relates the evidence to
the needs of practitioners and patients [3]. However,
treatment recommendations in guidelines are often
based on expert opinion and low levels of evidence,
which make them prone to biases and prejudices [4].
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reproduction in any medium, provided the ortherefore pose problems [4], as they may influence treat-
ment recommendations [5,6].
The potential effects of conflicts of interest might have
profound effects on health care because guidelines are
written to influence the practice of physicians [7] and
can be used for economic prioritisation [8]. Studies of
conflicts of interest have found that up to 87% of guide-
line authors had interactions with drug companies [8,9].
Many of these conflicts are not disclosed because guide-
line issuing bodies do not publish this information [10]
or because the authors choose not to disclose them [11].
This makes it likely that previous studies, which have
relied on disclosed information, have underestimated the
actual prevalence of conflicts of interest.
In Denmark, a nation of approximately 5.6 million
inhabitants, there are around 22,500 practising physi-
cians, 8.5% of which have a registered affiliation with a
drug company [12]. Any physician wishing to receivel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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permission through the Danish Health and Medicines
Authority and all physicians with permissions are named
on a publicly available list with information on company
and type of affiliation, but without financial data [13]. Simi-
lar to the US Physician Payments Sunshine Act [14], the
list makes it possible to study the level of underreporting
of conflicts of interest among guideline authors [15].
Our aims were:
 to determine the prevalence and types of conflicts of
interest among authors of clinical practice guidelines
published by Danish specialty societies;
 to estimate the proportion of disclosed conflicts of
interest;
 to describe the methodology used in the guidelines.
Methods
In Denmark there are 38 Danish specialty societies as
defined by the list of the Organization of Danish Medical
Societies [16]. Currently, national clinical practice guide-
lines are produced by individual societies and some are
produced jointly. Each society differs in relation to how
many guidelines they produce and how frequent they
are updated. While the guidelines are not officially
sanctioned by national or local health authorities, nor
directly affect coverage decisions, the guidelines set stan-
dards for best practice and are used by physicians for
clinical decision making. We sampled guidelines from
each of the 38 Danish specialty societies, but excluded
guidelines from non-clinical societies (e.g. radiology and
pathology).
Selection of guidelines
In March 2012, using the website for each specialty soci-
ety, one observer included the five most recent drug
guidelines published from July 2010. We limited the
number to five in order to avoid clustering by specialties
with many guidelines. As we focused on conflicts of
interest in relation to drugs, we selected guidelines with
a focus on drug treatment of medical conditions. For ex-
ample, for anaesthesia we included a guideline on strat-
egies for sedation, but excluded one on tracheotomy. In
case of multiple guidelines of similar publication date,
we selected them randomly. Societies without guidelines
on their website were contacted by e-mail to determine
whether any guidelines had been published. Guidelines
referenced on the societies' website that had been devel-
oped by other national or international organisations
were not considered a guideline for the particular soci-
ety. Guidelines made in collaboration between different
specialties were included in a separate category. Some
societies had not produced five guidelines meeting our
selection criteria and in those cases we included thosethat were available. A second observer verified the selec-
tion of guidelines according to our criteria. For each
society, we obtained information as to whether the soci-
ety had produced an instruction manual for guideline
preparation.
Guideline information
For each included guideline, two observers independ-
ently extracted information on title, date, number of
authors, names of authors, funding of guideline and
disclosures of conflicts of interest into a standardised
datasheet. Disagreements were resolved through discus-
sion. We contacted the specialty society for missing
information on date of publication and funding.
Conflicts of interest
We used the publicly available Danish registry of
authorization to practise medicine to ensure the identity
of authors and that they were physicians [17]. For each
author, information on conflicts of interest was identified
using the disclosure list of the Danish Health and Medi-
cines Authority [13]. The list is updated continuously
and we used three different versions from the period
June 2010 to March 2012. If we were uncertain about
whether a guideline author matched a physician on the
disclosure list (e.g. due to variation in spelling of the
name), we contacted the guideline issuing specialty soci-
ety and the Danish Health and Medicine Authority for
clarification. Two observers extracted information on
conflicts of interest and disagreements were resolved
through discussion. We coded a conflict of interest to be
present if an author had an affiliation with a drug com-
pany up to 3 years prior to the published guideline, simi-
lar to the ICMJE criteria for biomedical journals [18].
When we were in doubt, we obtained additional infor-
mation by applying for this through the Danish Health
and Medicines Authority.
The type of conflict of interest with drug companies
was classified into the following categories, which we de-
fined a priori based on our previous experience with the
disclosure list [12]:




Authors who have received reimbursement for confer-
ence expenses or fees for single activities such as speak-
ing at only one meeting are not listed on the disclosure
list.
For societies with an instruction manual for guideline
preparation, we coded whether the manual contained
information on disclosure of conflicts of interest.
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Our datasheets were developed using a pilot version on
one guideline on drug treatments from each of five
randomly selected specialty societies.
Guideline methodology
We initially planned to use the AGREE II instrument to as-
sess the reporting of guideline methodology [19], but due
to the low standards of reporting we encountered in our
pilot study, we decided to use a simplified version adapted
for key domains. For each guideline, two observers inde-
pendently extracted information on description of methods
for guideline development, use of references, and grading
of types of evidence. Use of references was categorized as:
references in text (for example when a particular drug was
recommended in the text and a trial of this drug was cited),
references, but not in text (when the references were at the
end of the guideline only), and no references. We coded
grading of evidence to be present if authors described the
levels of evidence behind specific recommendations or the
strength of recommendations according to a system (for
example Ia, Ib, IIa, IIb, III, IV or A, B, C, D).
Data analysis
We calculated the prevalence of disclosed and undisclosed
conflicts of interest overall, at guideline level, and at spe-
cialty society level. For authors with conflicts of interest,
we calculated the proportions of the individual types of
conflicts of interest. Guidelines made in collaboration be-
tween different specialties were analysed separately.
Sensitivity analysis
The estimated overall prevalence of authors with con-
flicts of interest depends on the number of authors per
society and the prevalence of conflicts of interest at soci-
ety level. We therefore performed a simple sensitivity
analysis to test the robustness of our results. We esti-
mated the prevalence as an average of the mean preva-
lence of conflicts of interest among individual societies,
assigning each society the same weight.
We also tried to quantify to which extent authors
without conflicts of interest according to the disclosure
list had such conflicts, in a random sample of 25% of the
authors. We searched the authors’ conflicts of interest
statements in scientific publications published in the
three years prior to the guideline data, searched Google
by combining their names with names of companies that
authors of the same guideline were affiliated with, and
contacted the Danish Health and Medicines Authority
for additional information.
Ethical approval
This study did not require ethical approval as it was
based on publicly available information.Results
We included 45 clinical practice guidelines, 40 from 14
Danish specialty societies and 5 collaborative guidelines
(Figure 1), with a total of 257 guideline authors. We
excluded two authors who were psychologists and one
midwife resulting in 254 physician authors. The number
of authors per guideline ranged from 1 to 16 (median 5).
As 7 authors participated in 2 guidelines, there were 247
unique authors. Two guidelines (4%) contained informa-
tion about funding. Six drug companies supported the
distribution of a guideline, but not its development. In
the other guideline with information on funding, two
medical societies and the Danish Institute for Rational
Pharmacotherapy funded the guideline development.
According to the specialty societies' replies to our
emails, none of the other 43 guidelines had received
funding from drug companies.
Conflicts of interest
Only one guideline (2%) included a conflicts of interest
statement for three of its four authors; all three were
conflicted. We identified conflicts of interest for 132
additional authors, giving a total of 135 out of 254
authors (53%) with conflicts of interest. The true preva-
lence of conflicts of interest of guideline authors ranged
from 0% to 100% among individual guidelines (Figure 2).
Forty-three guidelines (96%) had one or more authors
with a conflict of interest, and in only two guidelines
were all authors without conflicts (4%). In 24 guidelines
(53%), the majority of authors had conflicts of interest
and in 8 guidelines (18%), all authors had conflicts of
interest.
The most common type of conflict was consultant/
advisory board member/employee followed by speaker/
educational activities, investigator/research collaboration
and equity/stockholder (Table 1).
The lowest prevalence of authors with conflicts was
found for the Danish Society of Anaesthesiology and
Intensive Care (14%), the Danish Paediatric Society
(23%) and the Danish Society of Neurology (25%)
(Table 2). The highest prevalence was found for the Da-
nish Society of Dermatology (100%) and the Danish So-
ciety of Endocrinology (100%).
Sensitivity analysis
The overall prevalence of conflicts of interest among
guideline authors changed from 53% to 57% in our
sensitivity analysis (simple average of percentage for
each specialty society). When we searched for additional
information about conflicts of interest among the 30
authors without conflicts (25% of 119) we found that 3
(10%) had conflicts that were not disclosed on the
Danish Health and Medicines Authority’s list, the reason
being that the activities predated our earliest available
Figure 1 Inclusion of guidelines produced by specialty societies.
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without conflicts, according to the list, actually had
conflicts, the prevalence changed from 53% to 58%.
Guideline methodology
A description of the methods used for guideline develop-
ment was found in 10 guidelines (22%). Nine of those
were produced by only two societies, the Danish Society
of Gastroenterology and Hepatology and the Danish
Society of Obstetrics and Gynaecology, and the tenth
guideline was a collaborative one. Twenty-seven guide-
lines (60%) included references in the text, 10 (22%)
used references, but did not include them in the text,
and 8 (18%) did not use references at all. Eleven guide-
lines (24%) graded the types of evidence; 10 of thoseFigure 2 Prevalence of conflicts of interest among author groups in twere produced by the same two societies the Danish
Society of Gastroenterology and Hepatology and the
Danish Society of Obstetrics and Gynaecology and one
by Danish Society of Gastroenterology and Hepatology
in collaboration with five other societies.
Six out of 14 societies had instruction manuals for
guideline preparation and none of those included
policies on conflicts of interest.
Discussion
We found that 53% of guideline authors had conflicts of
interest, corresponding to 43 out of 45 guidelines being
written by one or more authors with conflicts, and that
only 2% disclosed them, in just one guideline. Most
guidelines did not state how they were developed orhe 45 guidelines.
Table 1 Types of conflicts of interest among conflicted
guideline authors
(n = 135)
Consultant/advisory board member/employee 83 (61%)
Speaker/educational activities 77 (57%)
Investigator/research collaboration 65 (48%)
Equity/stock 10 (7%)
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ences in the text.
Our study was based on very comprehensive data from
the Danish Health and Medicines Authority, and physi-
cians and drug companies are required by law to report
their collaboration to the authority [20]. Our findings de-
monstrate that reliance on voluntary disclosure underesti-
mates the prevalence of conflicts of interest substantially.Table 2 Prevalence of authors’ conflicts of interest
according to specialty society












1 7 1 (14%)
Danish Society of
Cardiology
5 22 16 (73%)
Danish Society of Child
and Adolescent Psychiatry
5 19 9 (47%)
Danish Society of
Dermatology
1 3 3 (100%)
Danish Society of
Endocrinology




5 29 9 (31%)
Danish Society of
Haematology
2 17 11 (65%)
Danish Society of
Infectious Diseases




5 13 6 (46%)
Danish Society of
Nephrology
1 8 5 (63%)
Danish Society of
Neurology
1 8 2 (25%)
Danish Society of
Paediatrics
5 26 6 (23%)
Danish Society of
Respiratory Medicine
5 18 11 (61%)
Danish Society of
Rheumatology
2 17 13 (76%)
Collaborative guidelines 5 56 33 (59%)Using a publicly available disclosure list made it pos-
sible to identify undisclosed conflicts of interest, but one
limitation of the list is that drug company affiliations are
deleted as soon as the collaboration ends. As judged by
our sensitivity analysis, this seemed to have had little
impact on our results, but we suggest that such lists
include affiliations up to 3 years prior to the current
date, similar to the ICMJE criteria [18].
It is therefore likely that previous studies of conflicts
of interest among clinical guideline authors have
underestimated the prevalence of conflicts of interest, as
they have relied on voluntary disclosure. We note, how-
ever, that the underreporting of conflicts of interest in
our study of Danish guidelines may have been atypical,
e.g. US guidelines have more disclosures [8]. We found
that only six societies had instruction manuals for guide-
line preparation and none included policies on conflicts
of interest. Thus, lack of policies on conflict of interest dis-
closure may have caused the extraordinary underreporting
of conflicts of interest found in our study. On the other
hand, this lack of transparency cannot be excused by the
lack of explicit policies, as it is well known that it is import-
ant to declare conflicts of interest in biomedical publica-
tions, especially in clinical guidelines.
Albeit our study was based on Danish guidelines, our
sample represents 14 different specialties and we have
thereby obtained more comprehensive information on
the extent of conflicts of interest among guideline
authors than in other studies, which have usually only
included guidelines from a few specialties [8].
In a recent systematic review by Norris and colleagues,
the prevalence of conflicts of interest ranged widely
among the different studies included, from 18% to 100%
[8]. The large variation in prevalence may have several
explanations.
Firstly, the sources used for identifying conflicts of
interest may have been important. Many studies identi-
fied conflicts of interest solely based on authors’ disclo-
sures in guidelines, which will generally underestimate
the prevalence [7,21]. Other studies have identified con-
flicts of interest based on authors' disclosure in their
additional journal publications [11,22,23] or by surveys
[24,25]. However, such strategies are often inadequate
[9], e.g. many journals do not include disclosure state-
ments in their articles or have only started recently,
response rates in surveys were often low, and authors
often do not to disclose conflicts in their scientific publi-
cations [26,27]. A few studies have used other sources
such as US patent databases [22,28].
Secondly, what constitutes a conflict of interest may
also influence its prevalence. We coded a conflict of
interest to be present if authors had an affiliation with a
company up to 3 years prior to the published guideline.
This interval differs among studies [8] as do perceptions
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example, some studies included paid travel fees [9,21],
which we did not, as such conflicts are not listed on the
disclosure list. We coded any financial tie as a conflict of
interest, although some ties might be related to compan-
ies producing drugs not relevant to the guideline. How-
ever, this will likely be less important, as guideline
authors are usually affiliated with companies producing
drugs in areas where they are experts and write guide-
lines in the same areas.
Thirdly, the overall extent of conflicts of interest
among physicians varies between countries. In Denmark,
the prevalence is approximately 8.5% [12], whereas it is
14.1% among US physicians [29].
Public disclosure lists may assist guideline issuing bod-
ies in ensuring that all conflicts of interest are disclosed.
In order for guideline end-users to judge fully the pos-
sible influence of the conflicts of interest, information
on individual authors' income from drug companies is
also relevant. This information will be available with the
implementation of the US Sunshine act in 2014 [30],
which will provide a public and comprehensive register
of data about physicians’ financial relationships with the
drug and device industries [15,30]. Similarly, the Danish
disclosure list will in future include financial information
[31]. Apart from the improved transparency in relation to
guideline users, such registers may also assist researchers
studying conflicts of interest.
While disclosure improves transparency, it does not
remove the potential bias related to conflicts of interest
[5,6,32], and a better strategy is to prohibit authors with
conflicts from guideline production or minimise their
influence on formulating recommendations [33]. It has
been argued that authors without conflicts of interest
lack the content area knowledge and skills necessary to
interpret the scientific data. But this is a flawed argu-
ment. Industry relations, such as being on a company’s
speakers bureau or advisory board, does not serve any
academic purpose and authors can choose to avoid these
relationships. Furthermore, there is a substantial pool of
authors without conflicts [32]. Lastly, content area
experts often have preconceptions about treatment ef-
fects, which may bias their interpretation of the evidence
[34-36]. A better strategy would be to include more
methodologists as guideline authors as they are often
free from preconceptions and rarely have conflicts of
interest.
Conclusions
Conflicts of interest among guideline authors from Danish
specialty societies were common but very rarely disclosed.
Most guidelines also lacked transparency as to their devel-
opment and the evidence in support of the recommenda-
tions. Thus, there is a need for better management anddisclosure of conflicts of interest, and greater transparency
of guideline methodology. Publicly available and law-
enforced disclosure lists may assist guideline issuing bod-
ies in ensuring that all conflicts are disclosed.
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